Carastock.

Earnings date. 13 Nov 2023. Forward dividend & yield. N/A (N/A) Ex-dividend date. N/A. 1y target est. 10.29. Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock split BBCA dengan rasio 1:5, artinya 1 saham yang ada saat ini dipecah menjadi 5 saham baru. Jumlah saham yang beredar semakin banyak, harga makin terjangkau. Nilai nominal per saham BBCA dari Rp 62,5 menjadi Rp 12,5. Sedangkan jumlah saham BCA sebelum stock split sebanyak 24,65 miliar saham menjadi 123,27 …Discover historical prices for CARA stock on Yahoo Finance. View daily, weekly or monthly format back to when Cara Therapeutics, Inc. stock was issued. According to 6 analyst offering 12-month price targets in the last 3 months, Cara Therapeutics has an average price target of $18.17 with a high of $28.00 and a low of $4.00. Below is a summary of ...

According to our current CARA stock forecast, the value of CARA Therapeutics shares will drop by -19.87% and reach $ 0.746314 per share by December 3, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).

According to our current CARA stock forecast, the value of CARA Therapeutics shares will drop by -19.87% and reach $ 0.746314 per share by December 3, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).CARA stock recorded 12/30 (40%) green days with 12.33% price …Post #2,000. Item 8.01 Other Information. As previously disclosed, on August 23, 2021, Cara Therapeutics, Inc. (“Cara”) received approval of its New Drug Application for KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients from the U.S. Food and Drug Administration (the “Approval Milestone”).

Cara Therapeutic stock price live 0.97, this page displays NASDAQ CARA stock exchange data. View the CARA premarket stock price ahead of the market session or assess the after hours quote.The firm currently boasts a market capitalization value of $187.83 million alongside a price-earnings ratio of -2.23 and beta of 0.87. Nonetheless, with exponential growth attainable through various regulatory approvals, the research-based biopharmaceutical company appears primed to deliver cutting-edge solutions that …Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Cara Therapeutics, Inc. (CARA) stock forecast and price target Find the latest Cara Therapeutics, Inc. CARA analyst stock forecast, price target, and recommendation trends with in-depth analysis ...

12 thg 3, 2018 ... Cara Operations, which also owns Swiss Chalet, saw sales grow 13.5 per cent in the fourth quarter to $774.9 million.

The firm currently boasts a market capitalization value of $187.83 million alongside a price-earnings ratio of -2.23 and beta of 0.87. Nonetheless, with exponential growth attainable through various regulatory approvals, the research-based biopharmaceutical company appears primed to deliver cutting-edge solutions that …Find out all the key statistics for Cara Therapeutics, Inc. (CARA), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...View the latest Cara Therapeutics Inc. (CARA) stock price, news, historical charts, analyst ratings and financial information from WSJ.Cara Therapeutics up ~21% so far this week as shares reach highest price in a month. SA NewsWed, Oct. 27, 2021 3 Comments. Get the latest news and real-time alerts from Cara Therapeutics, Inc ...Cara Therapeutics Inc (CARA) stock is trading at $4.98 as of 3:31 PM on Thursday, Mar 23, a decline of -$0.20, or -3.86% from the previous closing price of $5.18. The stock has traded between $4.94 and $5.33 so far today. Volume today is below average. So far 419,735 shares have traded compared to average volume of 832,550 shares.

What's Happening with CARA Stock Today. Cara Therapeutics Inc (CARA) stock is higher by 2.07% while the S&P 500 is higher by 1.41% as of 3:38 PM on Wednesday, Mar 29. CARA is higher by $0.10 from the previous closing price of $4.94 on volume of 309,020 shares. Over the past year the S&P 500 is down -13.05% while CARA …Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing. Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.Trailing 12-Months. Asset Growth. -40.69%. Trailing 12-Months. Cara Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven ...

CARA Stock Summary. The ratio of debt to operating expenses for CARA THERAPEUTICS INC is higher than it is for about merely 4.66% of US stocks. With a year-over-year growth in debt of -65.15%, CARA THERAPEUTICS INC's debt growth rate surpasses only 3.38% of about US stocks. In terms of volatility of its share price, CARA …Analyst Forecast. According to 8 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $15.13, which is an increase of 1,472.28% from the latest price.

As of Friday, March 17, Cara Therapeutics Inc’s CARA share price has dipped by 5.19%, which has investors questioning if this is right time to buy.Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ...24 thg 11, 2023 ... Quant Rating History · Go Premium to see CARA Quant Rating · Navigate the Stock Market with Seeking Alpha.585.00. +10.63%. 14.84M. View the real-time Cara Therapeutic (NASDAQ CARA) share price and assess historical data, charts, technical analysis and the share chat forum.Get the latest Cara Therapeutics, Inc. (CARA) stock news and headlines to help you in your trading and investing decisions. CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of ...

Cara Therapeutics Announces Positive Topline Results CARA: Cara Therapeutics, Inc. 2022-06-30 07:00:00 Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Nostalgia Paresthetica CARA: Cara Therapeutics, Inc. 2022-06-30 07:00:00 Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase ...

Nov 13, 2023 · Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend. Find the latest analyst research for Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com. Get the latest Cara Therapeutics, Inc. (CARA) stock news and headlines to help you in your trading and investing decisions. Cara Therapeutics' Q4 earnings EPS loss was $0.56 per share. Read why I am looking to quickly book some profits in CARA stock.CARA Stock 12 Months Forecast. $14.10. (1230.19% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $14.10 with a high forecast of $25.00 and a low forecast of $3.50. The average price target represents a 1230.19% change from the last price of $1.06.Beberapa perusahaan sekuritas saat ini sudah menyediakan platform jual beli saham, termasuk tahapan cara membeli saham bagi pemula atau cara membeli saham perusahaan bagi masyarakat awam. Dikutip dari laman Yuknabungsaham yang dikelola PT Bursa Efek Indonesia (BEI), Selasa (9/3/2021), untuk cara membeli saham, investor …Cara Therapeutics Inc (CARA) stock is trading at $5.51 as of 3:36 PM on Tuesday, Mar 21, a gain of $0.21, or 3.96% from the previous closing price of $5.30. The stock has traded between $5.31 and $5.53 so far today. Volume today is below average.Aug 24, 2021 · CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article. Nov 28, 2023 · Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $152.77M. -68.8%. Market Cap / Employee. The market cap of a ...

Cara Therapeutics, Inc. Common Stock. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is ... Where the stock market will trade today based on Dow Jones Industrial Average, S&P 500 and Nasdaq-100 futures and implied open premarket values. Commodities, currencies and global indexes also shown.Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing. Instagram:https://instagram. making money with optionshere real estate investingbest account for retirementlow float stocks screenerex dividend date calendartradeez The Cara Therapeutics stock price fell by -1.90% on the last day (Wednesday, 29th Nov 2023) from $0.98 to $0.96. During the last trading day the stock fluctuated 7.37% from a day low at $0.95 to a day high of $1.02. The price has fallen in 6 of the last 10 days and is down by -12.47% for this period. Volume has increased on the last day by 227 ... best va home loan lender Simply Wall St. May 25, 2023 at 6:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid ...The Trend in the Analyst Price Target. CARA's average price target has moved down $22.12 over the prior 42 months. Over the past 45 weeks, CARA's average upside potential has been 426.28%. Date.